Key points are not available for this paper at this time.
Abstract Introduction Neuroendocrine neoplasms (NENs) are classified as neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed neuroendocrine and nonneuroendocrine neoplasms (MiNENs) according to World Health Organization classification. We present our experience of NENs of the gallbladder (GB) from a high‐volume cancer hospital. Materials and Methods The present study is a retrospective analysis of all patients with GB NENs who presented between January 2015 and June 2023. The patient details and treatment received with follow‐up were noted. The primary endpoint was overall survival (OS). Results A total of 147 patients were included in the study. The median age was 52 (27–81) years. There was a female predominance (70.7%). NEC was the most common subtype (84.4%) followed by MiNEN (12.9%) and NET (2.7%). The most common stage at presentation was metastatic (70.7%) followed by locally advanced (21.8%), and early disease (7.5%). The median follow‐up was 9.92 (1.77–76.06) months. Median OS was 6.14 (3.93–8.35) months. Median OS in patients who received multimodality treatment was 20.20 (17.99–22.41) months versus 4.00 (2.91–5.10) months in those who did not receive it. Conclusion GB NENs are rare, but aggressive tumors with NEC being the most common type. Multimodality treatment yields favorable outcomes. However, the development of better systemic therapy is needed to help improve survival further.
Nandy et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: